Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | B2M LOH |
Therapy | Pembrolizumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
B2M LOH | melanoma | predicted - resistant | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, the presence of B2M loss of heterozygosity (LOH) in the pre-treatment biopsies was significantly associated with worse overall survival (p=0.006) in melanoma patients treated with Keytruda (pembrolizumab) (PMID: 29070816). | 29070816 |
PubMed Id | Reference Title | Details |
---|---|---|
(29070816) | Resistance to checkpoint blockade therapy through inactivation of antigen presentation. | Full reference... |